Instructions for Atorvastatin Teva
English product name
Atorvastatin-Teva
Release form
tab. film sheath, 20 mg: 30 or 90 pcs.
Description Atorvastatin
The tablets are covered with a film shell of white or almost white, capsule-shaped, with an engraving of "93" on one side and "7311" on the other.
1 tab.
calcium atorvastatin (converted to atorvastatin) 20.72 mg (20 mg)
Auxiliary substances:
lactose monohydrate - 189.88 mg,
povidone - 8.00 mg,
eudragite E100 (butylmethacrylate,
dimethylaminoethyl methacrylate and methylmethacrylate copolymer 1:2:1) - 3.00 mg,
alpha-tocopherol macrogola succinate - 6.00 mg,
sodium croscarmellose - 10.00 mg,
sodium stearyl fumarate - 2.40 mg,
Opadray YS-1R-7003 (titanium dioxide - 1 8750 mg,
hypromellose 2910 3cP (E464) - 1.7926 mg,
hypromellose 2910 5cP (E464) - 1.7926 mg,
macrogol-400 - 0.480 mg,
polysorbate-80 - 0.060 mg).
10 pcs - blister packs (3) - cardboard packs.
10 pcs - blister packs (9) - cardboard packs.
ATC codes
C10AA05 Atorvastatin
Clinical-pharmacological groups / Group affiliation
Hypolipidemic drug
Active substance
atorvastatin
Pharmacotherapy group Atorvastatin
Hypolipidemic agent - reductase inhibitor GMG-CoA
Testimony Atorvastatin
- Hypercholesterolaemia (heterozygous familial and nonfamilial hypercholesterolaemia
- (type IIa of Fredrikson's classification);
- combination (mixed) hyperlipidemia (types IIa and IIb of Fredrikson's classification);
- dysbetalipoproteinemia (type III of Fredrikson's classification)
- (as a supplement to the diet); family endogenous hypertriglyceridemia
- (type IV of Fredrikson's classification),
- diets-resistant;
- homozygous familial hypercholesterinemia with insufficient efficacy of diet therapy and other non-pharmacological
- treatments.
- Primary prevention of cardiovascular complications in patients without clinical signs of IBS,
- but with several risk factors of its development - age over 55 years,
- nicotine dependence,
- arterial hypertension,
- diabetes mellitus,
- low concentrations of Hs-HDL in blood plasma,
- genetic predisposition,
- including on the background of dylipidemia.
Method of use, course and dosage Atorvastatin
The treatment is carried out against a standard diet for patients with hypercholesterolemia. The dose is set individually, depending on the initial cholesterol level. Taken inside. The initial dose is usually ten mg once a day. The effect lasts two weeks and the maximum effect lasts four weeks. If necessary, the dose can be gradually increased at intervals of four weeks or more. The maximum daily dose is 80 mg.
- Nosology Atorvastatin (ICD codes)
- E78.0
- Pure hypercholesterolemia
- E78.1
- Pure hyperglyceridemia
- E78.2
- Mixed hyperlipidemia
Atorvastatin lowers cholesterol and lipoprotein levels in blood plasma by inhibiting GMG-CoA reductase and synthesizing cholesterol in the liver, and by increasing the number of hepatic LDL receptors on the cell surface, increasing LDL uptake and catabolism.
